Soluble ST2 does not change cardiovascular risk prediction compared to cardiac troponin T in kidney transplant candidates

Mira Keddis, Ziad M El-Zoghby, Bruce Kaplan, Jeffrey W. Meeusen, Leslie J. Donato, Fernando G Cosio, D Eric Steidley

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Solubility of Tumorigenicity 2 (sST2) is a novel biomarker that better stratifies risk of cardiovascular events (CVE) compared to cardiac troponin T(cTnT) in heart failure. We assessed the association of sST2 with the composite outcome of CVE and/or mortality compared to cTnT in kidney transplant candidates. Methods 200 kidney transplant candidates between 2010 and 2013 were included. Elevated sST2 was defined as ≥30ng/ml, cTnT≥0.01 ng/ml. Results Median age 53 (interquartile range (IQR) 42-61) years, 59.7% male and 82.0% white. 33.5% had history of CVE, 42.5% left ventricular hypertrophy (LVH) and 15.6% positive cardiac stress test. Elevated sST2 correlated with male gender, history of prior-transplants, CVE, positive stress test, LVH, elevated cTnT, anemia, hyperphosphatemia, increased CRP and non-transplanted status. Male gender, history of CVE and LVH were independent determinants of sST2. During 28 months (IQR 25.3-30), 7.5% died, 13.0% developed CVE and 19.0% developed the composite outcome. Elevated sST2 was associated with the composite outcome (hazard ratio = 1.76, CI 1.06-2.73, p = 0.029) on univariate analysis but not after adjusting for age, diabetes and cTnT (p = 0.068). sST2 did not change the risk prediction model for composite outcome after including age, diabetes, prior history of CVE and elevated cTnT. Conclusions Increased sST2 level is significantly associated with variables associated with CVE in kidney transplant candidates. sST2 was associated with increased risk of the composite outcome of CVE and/or death but not independent of cTnT. Larger studies are needed to confirm these findings and determine whether sST2 has added value in CV risk stratification in this cohort of patients.

Original languageEnglish (US)
Article numbere0181123
JournalPLoS One
Volume12
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

troponin T
kidney transplant
Transplants
Troponin T
Kidney
prediction
Left Ventricular Hypertrophy
hypertrophy
Composite materials
exercise test
Medical problems
Exercise Test
diabetes
Hyperphosphatemia
gender
Biomarkers
heart failure
value added
Solubility
anemia

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Soluble ST2 does not change cardiovascular risk prediction compared to cardiac troponin T in kidney transplant candidates. / Keddis, Mira; El-Zoghby, Ziad M; Kaplan, Bruce; Meeusen, Jeffrey W.; Donato, Leslie J.; Cosio, Fernando G; Steidley, D Eric.

In: PLoS One, Vol. 12, No. 7, e0181123, 01.07.2017.

Research output: Contribution to journalArticle

@article{fc3bf26a31844043ae4a8c9d22e50496,
title = "Soluble ST2 does not change cardiovascular risk prediction compared to cardiac troponin T in kidney transplant candidates",
abstract = "Background Solubility of Tumorigenicity 2 (sST2) is a novel biomarker that better stratifies risk of cardiovascular events (CVE) compared to cardiac troponin T(cTnT) in heart failure. We assessed the association of sST2 with the composite outcome of CVE and/or mortality compared to cTnT in kidney transplant candidates. Methods 200 kidney transplant candidates between 2010 and 2013 were included. Elevated sST2 was defined as ≥30ng/ml, cTnT≥0.01 ng/ml. Results Median age 53 (interquartile range (IQR) 42-61) years, 59.7{\%} male and 82.0{\%} white. 33.5{\%} had history of CVE, 42.5{\%} left ventricular hypertrophy (LVH) and 15.6{\%} positive cardiac stress test. Elevated sST2 correlated with male gender, history of prior-transplants, CVE, positive stress test, LVH, elevated cTnT, anemia, hyperphosphatemia, increased CRP and non-transplanted status. Male gender, history of CVE and LVH were independent determinants of sST2. During 28 months (IQR 25.3-30), 7.5{\%} died, 13.0{\%} developed CVE and 19.0{\%} developed the composite outcome. Elevated sST2 was associated with the composite outcome (hazard ratio = 1.76, CI 1.06-2.73, p = 0.029) on univariate analysis but not after adjusting for age, diabetes and cTnT (p = 0.068). sST2 did not change the risk prediction model for composite outcome after including age, diabetes, prior history of CVE and elevated cTnT. Conclusions Increased sST2 level is significantly associated with variables associated with CVE in kidney transplant candidates. sST2 was associated with increased risk of the composite outcome of CVE and/or death but not independent of cTnT. Larger studies are needed to confirm these findings and determine whether sST2 has added value in CV risk stratification in this cohort of patients.",
author = "Mira Keddis and El-Zoghby, {Ziad M} and Bruce Kaplan and Meeusen, {Jeffrey W.} and Donato, {Leslie J.} and Cosio, {Fernando G} and Steidley, {D Eric}",
year = "2017",
month = "7",
day = "1",
doi = "10.1371/journal.pone.0181123",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Soluble ST2 does not change cardiovascular risk prediction compared to cardiac troponin T in kidney transplant candidates

AU - Keddis, Mira

AU - El-Zoghby, Ziad M

AU - Kaplan, Bruce

AU - Meeusen, Jeffrey W.

AU - Donato, Leslie J.

AU - Cosio, Fernando G

AU - Steidley, D Eric

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background Solubility of Tumorigenicity 2 (sST2) is a novel biomarker that better stratifies risk of cardiovascular events (CVE) compared to cardiac troponin T(cTnT) in heart failure. We assessed the association of sST2 with the composite outcome of CVE and/or mortality compared to cTnT in kidney transplant candidates. Methods 200 kidney transplant candidates between 2010 and 2013 were included. Elevated sST2 was defined as ≥30ng/ml, cTnT≥0.01 ng/ml. Results Median age 53 (interquartile range (IQR) 42-61) years, 59.7% male and 82.0% white. 33.5% had history of CVE, 42.5% left ventricular hypertrophy (LVH) and 15.6% positive cardiac stress test. Elevated sST2 correlated with male gender, history of prior-transplants, CVE, positive stress test, LVH, elevated cTnT, anemia, hyperphosphatemia, increased CRP and non-transplanted status. Male gender, history of CVE and LVH were independent determinants of sST2. During 28 months (IQR 25.3-30), 7.5% died, 13.0% developed CVE and 19.0% developed the composite outcome. Elevated sST2 was associated with the composite outcome (hazard ratio = 1.76, CI 1.06-2.73, p = 0.029) on univariate analysis but not after adjusting for age, diabetes and cTnT (p = 0.068). sST2 did not change the risk prediction model for composite outcome after including age, diabetes, prior history of CVE and elevated cTnT. Conclusions Increased sST2 level is significantly associated with variables associated with CVE in kidney transplant candidates. sST2 was associated with increased risk of the composite outcome of CVE and/or death but not independent of cTnT. Larger studies are needed to confirm these findings and determine whether sST2 has added value in CV risk stratification in this cohort of patients.

AB - Background Solubility of Tumorigenicity 2 (sST2) is a novel biomarker that better stratifies risk of cardiovascular events (CVE) compared to cardiac troponin T(cTnT) in heart failure. We assessed the association of sST2 with the composite outcome of CVE and/or mortality compared to cTnT in kidney transplant candidates. Methods 200 kidney transplant candidates between 2010 and 2013 were included. Elevated sST2 was defined as ≥30ng/ml, cTnT≥0.01 ng/ml. Results Median age 53 (interquartile range (IQR) 42-61) years, 59.7% male and 82.0% white. 33.5% had history of CVE, 42.5% left ventricular hypertrophy (LVH) and 15.6% positive cardiac stress test. Elevated sST2 correlated with male gender, history of prior-transplants, CVE, positive stress test, LVH, elevated cTnT, anemia, hyperphosphatemia, increased CRP and non-transplanted status. Male gender, history of CVE and LVH were independent determinants of sST2. During 28 months (IQR 25.3-30), 7.5% died, 13.0% developed CVE and 19.0% developed the composite outcome. Elevated sST2 was associated with the composite outcome (hazard ratio = 1.76, CI 1.06-2.73, p = 0.029) on univariate analysis but not after adjusting for age, diabetes and cTnT (p = 0.068). sST2 did not change the risk prediction model for composite outcome after including age, diabetes, prior history of CVE and elevated cTnT. Conclusions Increased sST2 level is significantly associated with variables associated with CVE in kidney transplant candidates. sST2 was associated with increased risk of the composite outcome of CVE and/or death but not independent of cTnT. Larger studies are needed to confirm these findings and determine whether sST2 has added value in CV risk stratification in this cohort of patients.

UR - http://www.scopus.com/inward/record.url?scp=85024477042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024477042&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0181123

DO - 10.1371/journal.pone.0181123

M3 - Article

C2 - 28704488

AN - SCOPUS:85024477042

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e0181123

ER -